Roche Gets Atezolizumab Applications Rolling
This article was originally published in The Pink Sheet Daily
Executive Summary
With the PD-L1 inhibitor under review at FDA for bladder cancer, the Swiss pharma aims to complete the rolling submission for lung cancer by the end of the quarter.